Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 USD | +0.60% | -9.68% | +8.39% |
Financials (USD)
Sales 2024 * | 94.02M | Sales 2025 * | 72.9M | Capitalization | 113M |
---|---|---|---|---|---|
Net income 2024 * | -7M | Net income 2025 * | -29M | EV / Sales 2024 * | 1.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.55 x |
P/E ratio 2024 * |
-20
x | P/E ratio 2025 * |
-5.61
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | +2.99% | ||
1 week | -7.80% | ||
Current month | -21.33% | ||
1 month | -19.86% | ||
3 months | +6.52% | ||
6 months | +33.98% | ||
Current year | +10.65% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 58 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 1.68 | +0.60% | 290 171 |
24-04-22 | 1.67 | 0.00% | 257,899 |
24-04-19 | 1.67 | -3.47% | 505,550 |
24-04-18 | 1.73 | -1.70% | 198,849 |
24-04-17 | 1.76 | -5.38% | 585,231 |
Delayed Quote Nasdaq, April 23, 2024 at 10:25 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.65% | 113M | |
-0.57% | 103B | |
+3.60% | 96.73B | |
+1.34% | 21.31B | |
-15.70% | 21.21B | |
-6.26% | 18.79B | |
-42.14% | 16.37B | |
-22.43% | 13.68B | |
+6.73% | 13.44B | |
+24.02% | 10.98B |
- Stock Market
- Equities
- CTMX Stock